Title:Congenital Bleeding Disorders and COVID-19 - An Emphasis on the Role
of Thrombosis as One of the Main Causes of Morbidity and Mortality in
COVID-19
Volume: 22
Issue: 2
Author(s): Akbar Dorgalaleh*, Fatemeh Narouei, Mansur Asadi, Hassan Morovati Khamsi and Mohammad Saeed Gholami
Affiliation:
- Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences,
Tehran, Iran
Keywords:
COVID-19, hypercoagulability, hypocoagulability, thrombosis, congenital bleeding disorders, SARS-CoV-2.
Abstract: A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19),
with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with
inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against
COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up
observations revealed this effect, at least among patients with moderate to severe congenital bleeding
disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited
hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet
the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and
thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration
of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19.
